Author: Kevin Grogan

Ferring Pharmaceuticals has acquired the assets of the USA’s BioSurface Engineering Technologies (BioSET), including two Phase III-ready ‘orthobiologics’ designed to improve bone repair.

The National Institute for Health and Care Excellence has caused a stir with its proposed measures to tackle antibiotic resistance, which include setting up “antimicrobial stewardship teams” to keep a closer watch on local prescribing.

Sanofi has linked up with Lead Pharma of the Netherlands to develop drugs for a broad range of autoimmune disorders, including rheumatoid arthritis, psoriasis and inflammatory bowel disease.

Sprout Pharmaceuticals has resubmitted flibanserin, its twice-rejected, once-daily non-hormonal pill for hypoactive sexual desire disorder in premenopausal women, to the US Food and Drug Administration.

As it bids to halt the decline of its respiratory business across the pond, GlaxoSmithKline has unveiled Jack Bailey as replacement for Deirdre Connelly as president of US pharmaceuticals.